Jpmorgan Chase & CO Rezolute, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Rezolute, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 8,685 shares of RZLT stock, worth $37,171. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,685Holding current value
$37,171% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding RZLT
# of Institutions
62Shares Held
38.5MCall Options Held
1.6KPut Options Held
24.6K-
Federated Hermes, Inc. Pittsburgh, PA11.3MShares$48.3 Million0.13% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.8MShares$12 Million1.99% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.58MShares$11 Million0.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.93MShares$8.27 Million0.0% of portfolio
-
Blackstone Inc New York, NY1.74MShares$7.47 Million0.04% of portfolio
About Rezolute, Inc.
- Ticker RZLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,600
- Market Cap $166M
- Description
- Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...